Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology

Author:

Bikdeli Behnood123,McAndrew Thomas3,Crowley Aaron3,Chen Shmuel13,Mehdipoor Ghazaleh3,Redfors Björn134,Liu Yangbo3,Zhang Zixuan3,Liu Mengdan3,Zhang Yiran3,Francese Dominic P.3,Erlinge David5,James Stefan K.6,Han Yaling7,Li Yi7,Kastrati Adnan8,Schüpke Stefanie8,Stables Rod H.910,Shahzad Adeel9,Steg Philippe Gabriel1112,Goldstein Patrick13,Frigoli Enrico14,Mehran Roxana315,Valgimigli Marco14,Stone Gregg W.315

Affiliation:

1. Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States

2. Center for Outcomes Research & Evaluation, Yale School of Medicine, Yale University, New Haven, Connecticut, United States

3. Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, United States

4. Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

5. Department of Cardiology, Lund University, Lund, Sweden

6. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

7. Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China

8. Department of Cardiology, Deutsches Herzzentrum München, Technische Universität, Munich, Germany

9. Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

10. University of Liverpool, Liverpool, United Kingdom

11. Hôpital Bichat, Paris, France

12. Imperial College, Royal Brompton Hospital, London, United Kingdom

13. Lille University Hospital, Lille, France

14. Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

15. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States

Abstract

Abstract Background Individual randomized controlled trials (RCTs) of periprocedural anticoagulation with bivalirudin versus heparin during percutaneous coronary intervention (PCI) have reported conflicting results. Study-level meta-analyses lack granularity to adjust for confounders, explore heterogeneity, or identify subgroups that may particularly benefit or be harmed. Objective To overcome these limitations, we sought to develop an individual patient-data pooled database of RCTs comparing bivalirudin versus heparin. Methods We conducted a systematic review to identify RCTs in which ≥1,000 patients with acute myocardial infarction (AMI) undergoing PCI were randomized to bivalirudin versus heparin. Results From 738 identified studies, 8 RCTs met the prespecified criteria. The principal investigators of each study agreed to provide patient-level data. The data were pooled and checked for accuracy against trial publications, with discrepancies addressed by consulting with the trialists. Consensus-based definitions were created to resolve differing antithrombotic, procedural, and outcome definitions. The project required 3.5 years to complete, and the final database includes 27,409 patients (13,346 randomized to bivalirudin and 14,063 randomized to heparin). Conclusion We have created a large individual patient database of bivalirudin versus heparin RCTs in patients with AMI undergoing PCI. This endeavor may help identify the optimal periprocedural anticoagulation regimen for patient groups with different relative risks of adverse ischemic versus bleeding events, including those with ST-segment and non-ST-segment elevation MI, radial versus femoral access, use of a prolonged bivalirudin infusion or glycoprotein inhibitors, and others. Adherence to standardized techniques and rigorous validation processes should increase confidence in the accuracy and robustness of the results.

Funder

The Medicines Company

Cardiovascular Research Foundation

Publisher

Georg Thieme Verlag KG

Subject

Hematology

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3